Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence
Tirzepatide shows promise as an insulin add-on for Type 1 diabetes patients with obesity, addressing a previously underserved treatment gap.
This systematic review synthesizes randomized and real-world evidence for tirzepatide use alongside insulin in adults with Type 1 diabetes and obesity, a therapeutic gap with high unmet need. The review supports the emerging role of tirzepatide as an insulin adjunct in T1D, extending its established T2D benefits to a more complex patient population.
What the study was
- Study design
- Systematic review (RCT and real-world evidence)
- Population
- Adults with Type 1 diabetes and overweight or obesity on insulin
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Endocrinology, Diabetes & Metabolism
Why it surfaced
SR on tirzepatide in T1D+obesity fills a critical evidence gap; T1D+obesity is an underserved population with high cardiometabolic burden and no licensed GLP-1/GIP options in most markets.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.